Teva gains rights to biosimilars from Samsung Bioepis
Teva Pharmaceutical (TEVA) and Samsung Bioepis agreed to license two FDA-approved biosimilars. Teva gains US commercialization rights for etanercept-ykro immediately and infliximab-abda in Q3 2027. Samsung Bioepis retains regulatory and manufacturing responsibilities. The deal is expected to close by the end of 2026, subject to approvals.
How this was made
The 30-second read
Why it matters
The deal adds two FDA‑approved products to Teva's U.S. portfolio, potentially increasing sales and margin in a competitive market.
Market read
The agreement is a material corporate development for Teva, likely to influence its stock and the broader biosimilar sector.
What to watch
The agreement does not include pricing terms; profit contribution depends on future reimbursement decisions
Background
Teva, a major generic and biosimilar manufacturer, is expanding its immunology biosimilar lineup through a partnership with Samsung Bioepis, a joint venture of Samsung and Biogen.
Ticker impact
Teva Pharmaceutical Industries signed a license and commercialization agreement with Samsung Bioepis for two FDA‑approved biosimilars, gaining U.S. rights to etanercept‑ykro and infliximab‑abda.
likely upward pressure as investors price in future revenue from the new biosimilars
Biosimilar launches typically boost margins; the deal is material for Teva's growth strategy and is newly disclosed.
Market effects
strengthens the U.S. biosimilar market and may pressure rivals like Amgen and AbbVie
adds to Israel's pharma export outlook
shows continued consolidation of biosimilar manufacturing in Asia
Counterpoint
If regulatory delays occur, the anticipated revenue boost could be postponed, weighing on the stock
Key entities
- companyTeva Pharmaceutical Industries
U.S.-listed Israeli pharma company acquiring U.S. rights to biosimilars
- companySamsung Bioepis
South Korean biosimilar developer and partner in the agreement
